What is the 13F Pro Quality Score for CGEM?

13F Pro ranks Cullinan Therapeutics, Inc. (CGEM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CGEM's current score at https://13fpro.ai/research/CGEM (free sign-up required for the full ranking).

Which hedge funds own the most CGEM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CGEM include Lynx1 Capital Management, MPM BioImpact, BVF /IL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CGEM as soon as new 13F filings post.

Where does 13F Pro source CGEM data?

All Cullinan Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cullinan Therapeutics, Inc. files with the SEC under CIK 1789972. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CGEM in?

Cullinan Therapeutics, Inc. (CGEM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CGEM research updated on 13F Pro?

CGEM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cullinan Therapeutics, Inc.(CGEM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1789972 CGEM stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CGEM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cullinan Therapeutics, Inc. (CGEM), a Healthcare sector company. CGEM is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Cullinan Therapeutics, Inc. reports net income of $-49.7M, free cash flow of $-46.0M. Top institutional holders of CGEM by reported 13-F value include Lynx1 Capital Management, MPM BioImpact, BVF /IL, based on the most recent SEC filings. CGEM trades on the Nasdaq exchange and files with the SEC under CIK 1789972. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CGEM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cullinan Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-49.7M

Free Cash Flow

Q1 2026

$-46.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 $0.00FY23 —FY24 —FY25 —

Net Income

-31.4% YoY

$-219.9MFY 2025

FY22 $111.2MFY23 $-153.2MFY24 $-167.4MFY25 $-219.9M

Operating Income

-22.7% YoY

$-241.6MFY 2025

FY22 $144.6MFY23 $-191.1MFY24 $-196.9MFY25 $-241.6M

EPS (Diluted)

—FY 2025

FY22 $2.38FY23 $-3.69FY24 —FY25 —

Total Assets

-27.9% YoY

$448.4MFY 2025

FY22 $561.1MFY23 $484.2MFY24 $621.8MFY25 $448.4M

Op. Cash Flow

-21.0% YoY

$-175.8MFY 2025

FY22 $-126.7MFY23 $-134.3MFY24 $-145.3MFY25 $-175.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	—	$0.00 -100.0%	$18.9M	$0.00
Net Income	$-219.9M -31.4%	$-167.4M -9.3%	$-153.2M -237.7%	$111.2M +269.6%	$-65.6M -26.6%	$-51.8M
Operating Income	$-241.6M -22.7%	$-196.9M -3.1%	$-191.1M -232.1%	$144.6M +312.9%	$-68.0M -12.6%	$-60.3M
EPS (Diluted)	—	—	$-3.69 -255.0%	$2.38 +256.6%	$-1.52	—
Total Assets	$448.4M -27.9%	$621.8M +28.4%	$484.2M -13.7%	$561.1M +28.3%	$437.2M +103.6%	$214.7M
Operating Cash Flow	$-175.8M -21.0%	$-145.3M -8.2%	$-134.3M -6.0%	$-126.7M -191.6%	$-43.4M -45.9%	$-29.8M

AI Insight: CGEM Financial Trends

Cullinan's equity base has eroded 38% from $656M to $409M over six quarters as cash burn persists with zero revenue.

• Operating losses widened sharply in Q2 2025 to -$76M before moderating back to -$54M in Q1 2026.

• Equity has declined every quarter from $656M in Q2 2024 to $409M in Q4 2025 — a $247M drawdown in six quarters.

• Operating cash outflows spiked to -$58M in Q2 2025 but partially normalized to -$46M in Q1 2026.

⚠ No revenue across all observable periods; runway depends entirely on existing cash reserves shrinking each quarter.

⚠ Equity trajectory implies continued balance sheet erosion; pace of decline must slow or a capital raise becomes necessary.

AI Insight: CGEM Ratio Trends

CGEM's capital returns have deteriorated sharply, with ROIC worsening from -30.5% in Q2 2024 to -54.1% in Q4 2025 as cash burn accelerates.

• ROIC deteriorated steadily from -30.5% in Q2 2024 to -54.1% in Q4 2025, signaling accelerating capital consumption.

• ROE deepened from -25.6% in Q2 2024 to -49.6% in Q4 2025, reflecting sustained and growing net losses relative to equity.

• A sharp spike in Q2 2025 — ROE hit -56.9%, ROA -53.8%, ROIC -61.6% — suggests a one-off charge or elevated spend that quarter.

⚠ Q1 2026 return metrics are absent; confirmation of whether the Q4 2025 burn rate persists or stabilizes is critical.

⚠ ROA worsened from -24.7% to -45.2% over six quarters — cash runway and asset base adequacy warrant close monitoring.

Get alerted when CGEM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cullinan Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CGEM

Lynx1 Capital Management LP
$127.4M8,963,500 sh
MPM BioImpact LLC
$108.7M7,648,268 sh
BVF INC/IL
$81.7M5,750,683 sh
BlackRock, Inc.
$63.2M4,449,966 sh
Kynam Capital Management, LP
$44.3M3,114,132 sh
STATE STREET CORP
$36.2M2,544,115 sh
VANGUARD CAPITAL MANAGEMENT LLC
$35.3M2,483,034 sh
Blue Owl Capital Holdings LP
$27.1M1,909,764 sh
RTW INVESTMENTS, LP
$24.2M1,705,960 sh
VR Adviser, LLC
$19.6M1,379,965 sh

Fund	Value	Shares
Lynx1 Capital Management LP	$127.4M	8,963,500
MPM BioImpact LLC	$108.7M	7,648,268
BVF INC/IL	$81.7M	5,750,683
BlackRock, Inc.	$63.2M	4,449,966
Kynam Capital Management, LP	$44.3M	3,114,132
STATE STREET CORP	$36.2M	2,544,115
VANGUARD CAPITAL MANAGEMENT LLC	$35.3M	2,483,034
Blue Owl Capital Holdings LP	$27.1M	1,909,764
RTW INVESTMENTS, LP	$24.2M	1,705,960
VR Adviser, LLC	$19.6M	1,379,965

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CGEM on your watchlist

Track score changes the day Cullinan Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CGEM a good stock to buy?

13F Pro's AI-powered analysis of Cullinan Therapeutics, Inc. (CGEM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CGEM are available on the CGEM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CGEM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CGEM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cullinan Therapeutics, Inc.'s investment landscape.